Leerink Partners Starts Monopar Therapeutics (MNPR) at Outperform
Tweet
Share
E-mailGet Alerts MNPR Hot Sheet
Price: $87.68 +0.06%
Rating Summary:
15 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Rating Summary:
15 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Join SI Premium – FREE
Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ: MNPR) with a Outperform rating and a price target of $115.00.
For an analyst ratings summary and ratings history on Monopar Therapeutics click here. For more ratings news on Monopar Therapeutics click here.
Shares of Monopar Therapeutics closed at $80.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gulfport Energy and Mobility Global to join S&P SmallCap 600
- Select Medical stockholders approve buyout by insider-led consortium
- Matinas BioPharma gets NYSE American compliance notice
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
